# WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

SJIF Impact Factor 7.421

Volume 7, Issue 4, 903-911

Research Article

ISSN 2278 - 4357

# COMPARISON OF INTUBATING CONDITIONS AND HAEMODYNAMIC CHANGES USING ROCURONIUM AND VECURONIUM BROMIDE DURING ENDOTRACHEAL INTUBATION

<sup>1</sup>Dr. Prithviraj Gomsale, <sup>2</sup>Dr. Lokare S. S., <sup>3</sup>Dr. Vaibhav Mahajan and <sup>4\*</sup>Dr. Deepak Phalgune

Article Received on 26 January 2018, Revised on 16 Feb 2018, Accepted on 08 March 2018, DOI: 10.20959/wjpps20184-11246

\*Corresponding Author
Dr. Deepak Phalgune
MD (P and SM), PhD,
Research Consultant, Poona
Hospital and Research
Centre, Pune.

#### **ABSTRACT**

**Background and Aims:** Use of suxamethonium as muscle relaxant is associated with various side effects, some of which are inconvenient while others may be potentially harmful. Considering various side effects of succamethonium the present study was undertaken to compare the onset of action, intubating conditions and hemodynamic parameters using vecuronium and rocuronium for laryngoscopy. **Methods:** Sixty patients scheduled for different surgical speciality posted for various elective procedures under general anaesthesia were randomly divided into two groups. Thirty patients in Group A and Group B were given intubating dose of rocuronium 0.6mg/kg and vecuronium 0.1 mg/kg

respectively Primary outcome measures were the onset of action whereas secondary outcome measure were intubating conditions and hemodynamic parameters using vecuronium and rocuronium for laryngoscopy. Comparison of quantitative and qualitative variables between groups was done using unpaired student's "t" test and chi-square test respectively using statistical package for social sciences. **Results:** Onset of action of rocuronium [59.2( $\pm$  4.0) seconds] was significantly shorter than v ecuronium [136.6( $\pm$  6.6) seconds] with p value 0.001. The duration of action of vecuroniun [45.3( $\pm$ 3.1) minutes] of was slight longer than rocuronium [41.1( $\pm$ 4.4) minutes ]with p value 0.001. There was no statistically significant difference in intubating conditions. **Conclusion:** Rocuronium can be used as a muscle relaxant for laryngoscopy and intubation over v ecuronium.

<sup>&</sup>lt;sup>1</sup>MBBS, DNB (Anaesthesia) Senior resident, Poona Hospital and Research Centre, Pune.

<sup>&</sup>lt;sup>2,3</sup>MD (Anaesthesia), Consultant Anaesthesiologist, Poona Hospital and Research Centre, Pune.

<sup>&</sup>lt;sup>4</sup>MD (P and SM), PhD, Research Consultant, Poona Hospital and Research Centre, Pune.

**KEYWORDS:** Rocuronium, v ecuronium, intubating conditions.

#### INTRODUCTION

Use of as muscle relaxant revolutionized anaesthesia practice by providing intense neuromuscular blockade of very rapid onset and ultra short duration, thereby greatly easing the maneuver of tracheal intubation. Since then, it has been widely used as a muscle relaxant of choice for most of the patients. But, its use is associated with various side effects, some of which are inconvenient while others may be potentially harmful. In addition, its use may be contraindicated in some situations.

The unwanted side-effects which may be encountered with suxamethonium include muscle fasciculations, post-operative myalgia, hyperkalemia, increased intraocular, intragastric and intracranial pressures, and cardiac arrhythmias. In addition to these potential problems, prolonged apnea may be encountered in individuals with atypical pseudocholinesterase. It may also induce malignant hyperthermia and myoglobinuria, a grave situation in susceptible patients. Thus, it falls short of an ideal muscle relaxant due to its potentially hazardous side effects, in spite of having the advantages of rapid action and quick recovery. Thus, the need for a rapid acting non-depolarizing neuromuscular blocking agent to replace suxamethonium for rapid sequence induction of anaesthesia has therefore been obvious for many years.

The search for better drugs to meet the properties of an ideal neuromuscular blocking agent, led to the development of new non- depolarizing neuromuscular blocking drugs. Recently, developed drugs of intermediate duration include vecuronium and atracurium which are, to a major extent, free from various side effects encountered with suxamethonium. However, even after intubating doses, onset time is relatively slow as compared with suxamethonium that of for rapid tracheal intubation. The use of high initial bolus dose of either atracurium or vecuronium shortens the onset time, but at the expense of a prolonged duration of action, which may be undesirable in certain situations.

The new addition in the list of neuromuscular blocking agents is rocuronium bromide, which fills the gap for an agent, with rapid onset while lacking the potentially adverse features associated with suxamethonium, retaining a medium duration of action and meeting most of the requirements of an ideal neuromuscular blocking agent.

Work carried out by various workers has confirmed the long held belief, that a rapid onset of action can be produced by compounds of relatively low potency. This concept was in part the basis for the development of rocuronium bromide. Rocuronium is an aminosteriod non depolarizing neuro muscular blocking agent used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical intubation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. The intubating dose of rocuronium is 0.6 mg/kg.<sup>[1]</sup> Vecuronium bromide is a muscle relaxant in the category of non-depolarizing blocking agents. Vecuronium bromide is indicated as an adjunct to general anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. The intubating dose for vecuronium bromide is 0.1 mg/kg.<sup>[2]</sup>

Considering the various side effects of succamethonium the present study was undertaken to compare the onset of action, intubating conditions and hemodynamic parameters using vecuronium and rocuronium for laryngoscopy.

#### MATERIAL AND METHODS

This prospective, randomised double-blind controlled study was conducted between October 2015 and December 2016. After scientific advisory committee and institutional ethics committee approval, written informed consent was obtained from all patients. Patients aged 18 to 60 years of either sex scheduled different surgical speciality posted for various elective procedures under general anaesthesia, and American Society of Anaesthesiologist (ASA) grade I and II were included. Pregnant or lactating women, patients having pre-existing problem of difficult intubation, paralysis or neuromuscular disorder, h/o drug intake that might affect neuromuscular blocking agent, and impaired renal or hepatic function were excluded from this study.

Out of 65 patients assessed for eligibility, after exclusion 60 patients were randomly divided into two equal groups of 30 each, using computer generated randomization code (Fig 1). We used website https://www.sealedenvelope.com/simple-randomiser/v1/lists for creating a randomization list with block size four. Group A patients and Group B patients were given intubating dose of rocuronium 0.6mg/kg and vecuronium 0.1 mg/kg respectively. An operation theatre nurse prepared syringes with rocuronium or vecuronium and put them into concealed envelopes according to the allocation orders. This was done under the supervision of senior anaesthesiologist. Researcher and patients were blind as to group assignment.

Pre-anaesthesia checkup was done one day prior to surgery. The patients were evaluated for any systemic diseases and laboratory investigations were recorded. Details of the procedure was explained to the patients. In operation theatre, adequate intravenous (IV) access was confirmed. Standard monitors were attached. Noninvasive blood pressure, pulse-oximeter, electrocardiogram, end tidal  $CO_2$  (ET  $CO_2$ ) were monitored after intubation. Before induction of anaesthesia, all patients were given IV glycopyrrolate 0.004 mg/kg, IV ondensetron 75 microgram/kg, and IV ranitidine 50 mg. The patients were pre-oxygenated with 100% oxygen for three minutes before induction. In all patients, anaesthesia was induced with IV fentanyl 2  $\mu$ g / kg, IV propofol 2-2.5 mg / kg. After abolition of eye reflex, intubating dose of muscle relaxant of either inj. rocuronium (0.6 mg/kg) or inj. Vecuronium (0.1mg/kg) as selected by randomization was given. The time of administration of relaxant was noted. Time in seconds from injection of study drug till train of four (TOF) score 0 was measured by intermittently noting response to TOF.

The degree of muscle relaxation was monitored with the help of TOF machine. Direct laryngoscopy was performed when TOF was 0 and the intubating conditions were observed according to "Copenhagen consensus rating scale". The time interval from the administration of the relaxant to the time at which TOF showed 0 was noted. The patient was then intubated with adequate size cuffed endotracheal tube and intermittent positive pressure ventilation was started with N<sub>2</sub>O and O<sub>2</sub> mixture through Bain circuit. All patients were maintained on nitrous oxide and oxygen mixture (2:1) and intermittent injection of rocuronium or vecuronium. Analgesics and sevoflurane were given as per requirement. Onset of action (assessed by TOF machine), intubating conditions such as laryngoscopy (jaw relaxation), vocal cord (position andmovement), response to intubation(coughing and limb movement), cardiovascular response(pulse rate, blood pressure, and SPO<sub>2</sub>) were observed and recorded at baseline, immediately after intubation and 10 minutes later. Intubating conditions were assessed as excellent, good or poor using Copenhagen consensus rating scale.

Copenhagen Consensus rating scale.

Intubating condition	Clinically acceptable		Clinically unacceptable	
variables	Excellent	Good	Poor	
Laryngoscopy	Easy	Fair	Difficult	
Vocal cords				
Position	Abducted	Intermediate	Closed	
Movement	None	Moving	Closing	
Response to intubation				
Movement of limbs	None	Slight	Vigorous	
Coughing	None	Diaphragmatic	Sustained (>10s)	

At the end of surgery, reversal was done with inj. neostigmine 50 microgram/kg and inj. glycopyrrolate 40 microgram/kg. After return of adequate respiratory effort and upper airway reflexes along with spontaneous eye opening, exturbation was done. The patient was shifted to recovery.

Laryngoscopy was defined as easy if jaw was relaxed, no resistance to blade in the course of laryngoscope, fair if the jaw relaxed, slight resistance to the blade and difficult if poor jaw relaxation, active resistance of the patient to laryngoscopy. Intubating conditions were defined as excellent if all variable listed under 'excellent' were present, good if only variable listed under 'excellent' or 'good' was present and poor if the presence of any variable listed under 'poor' was present.

Primary outcome measures were the onset of action whereas secondary outcome measure were intubating conditions and hemodynamic parameters using vecuronium and rocuronium for laryngoscopy.

On the basis of previously published study, [3] a sample size of 30 patients in each group was calculated by a formula [4] with 80 % power and 5 % probability of Type I error to reject null hypothesis. Data collected were entered in the Excel 2007 and analysis of data was done using Statistical Package for Social Sciences (SPSS) version 20, IBM, USA. The comparison of quantitative variables between the groups such as mean age, mean weight, mean heart rate, mean systolic BP, mean diastolic BP, mean SPO<sub>2</sub>, mean train of monitoring and mean duration of action was done using unpaired student's "t" test, whereas comparison of qualitative variables such as age group, gender, ASA grade, laryngoscopy status, vocal cord status and response to intubation was done by using chi-square test or Fisher's exact test. The confidence limit for significance was fixed at 95% level with p-value < 0.05.

## **RESULTS**

Out of 65 patients assessed for eligibility, 5 were excluded because of impaired renal function (2), impaired hepatic function (1), refused to participate (2). Sixty patients were randomly allotted, 30 patients in each group and were analyzed and compared (Fig.1).

Both groups were comparable with respect to mean age, age groups, sex distribution, mean weight, and ASA physical status (Table 1). As depicted in table 2, mean heart rate 10 minutes after intubation was significantly higher in vecuronium group but there was no statistically

significant difference in other heamodynamic parameters between the two groups. As shown in table 3, onset of action of rocuronium was significantly shorter than v ecuronium whereas the duration of action of vecuronium of was slight longer than rocuronium. There was no statistically significant difference in intubating conditions such as laryngoscopy status, vocal cord status and response to intubation.

Table 1: Demographic profile.

Demographic characteristic	Group A (N = 30)	Group B (N = 30)	p value
Mean age in years(SD)	37.2 (± 6.6)	36.4 (± 7.1)	0.500
Age in years (%)			
< 30	5(16.7)	5(16.7)	
30 < 40	15(50.0)	16(53.30)	0.002
40 < 50	9(30.0)	8(26.7)	0.993
>50	1(3.3)	1(3.3)	
Gender, no (%)			
Male	15 (50.0)	14 (46.7)	
Female	15 (50.0)	16 (53.3)	0.796
Mean weight in kg (SD)	60.7 (± 5.6)	60.3 (± 7.0)	0.809
ASA Grade (%)			
I	19 (63.3)	21(70.0)	0.584
II	11(36.7)	9(30.0)	0.384

**Table 2: Comparison of vital parameters.** 

Vital parameters	Group A (N = 30)	Group B (N = 30)	p value
Heart rate / minute (SD)			
Baseline	$81.7(\pm 4.4)$	$83.5(\pm 5.3)$	0.156
Immediate after intubation	$91.5(\pm 5.4)$	$93.5(\pm 4.7)$	0.131
After 10 minutes	$80.6(\pm 4.1)$	$83.2(\pm 5.2)$	0.039
Systolic BP (SD)			
Baseline	$126.9(\pm 5.0)$	$127.9(\pm 5.0)$	0.427
Immediate after intubation	$144.7(\pm 5.4)$	$146.7(\pm 5.5)$	0.161
After 10 minutes	$126.8(\pm 4.0)$	$128.6(\pm 5.4)$	0.143
Diastolic BP (SD)			
Baseline	$75.2(\pm 4.7)$	$77.9(\pm 5.6)$	0.181
Immediate after intubation	$87.9(\pm 4.7)$	$88.1(\pm 5.8)$	0.922
After 10 minutes	$75.7(\pm 4.9)$	$76.8(\pm 5.5)$	0.387
SPO <sub>2</sub> (SD)	100(0.0)	100(0.0)	0.999

Table 3: Intra operative comparison.

Parameters	Group A (N = 30)	Group B (N = 30)	p value
Train of four monitoring in seconds (SD)	$59.2(\pm 4.0)$	$136.6(\pm 6.6)$	0.001
<b>Duration of action in minutes (SD)</b>	41.1(±4.4)	45.3(±3.1)	0.001
Laryngoscopy status (%)			
Easy	30(100.0)	30(100.0)	0.999
Difficult	0(0.0)	0(0.0)	0.999
Vocal cord status (%)			
Abducted position	30(100.0)	30(100.0)	0.999
No movement	30(100.0)	30(100.0)	0.999
Response to intubation (%)			
No limb movement	30(100.0)	30(100.0)	0.999
No cough	30(100.0)	30(100.0)	0.999




Fig 1: CONSORT Diagram.

## **DISCUSSION**

In the present randomized controlled study onset of action, intubating conditions and hemodynamic parameters using vecuronium and rocuronium for laryngoscopy were compared in 60 patients, between 18 and 60 years of age scheduled for various elective surgeries under general anaesthesia. Onset of action of rocuronium was significantly shorter than vecuronium whereas the duration of action of vecuronium of was slight longer than rocuronium in the present study.

The studies conducted by J.M.K. H. Wierda etal<sup>[5]</sup>, Bartkowski RR et al<sup>[6]</sup> and Robertson EN et al<sup>[7]</sup> reported that rocuronium provided clinically acceptable intubating conditions in shorter time with least side effects as compared to succinvlcholine and vecuronium. The results of the above studies are comparable with our research. W.M. Schramm et al<sup>[8]</sup> reported that there was no significant changes in the mean arterial blood pressure after rocuronium(0.6 mg/kg) and vecuronium (0.1 mg/kg). Our study substantiated the findings. Lewy et al<sup>[9]</sup> reported that in doses upto 1.2 mg/kg rocuronium has minimal cardiovascular side effects both in healthy patients and those with cardiovascular disease. These results were consistent with findings of the present study. J.M.K. Wierda et al<sup>[5]</sup> and Neeraia Bharti etal<sup>[10]</sup> reported that the rate of development of neuromuscular block and hencethe onset of action was faster with rocuromium than vecuromium. Their findings are consistent with our study. Study conducted by Lin et al<sup>[11]</sup> observed that clinical durations of action were 44.2 +/- 13.2 min in rocuronium group and 42.5 +/- 9.1 min in vecuronium group respectively. In the present study, although duration of action of rocuronium was slightly but significantly less than that of vecuronium. Man TT et al<sup>[12]</sup> and Lin PL et al<sup>[11]</sup> reported that both rocuronium and vecuronium provided good to excellent intubating conditions. In our studies also we got same results. There are certain limitations in the present research such aspropofol used can depress the laryngeal reflexes and thus can act as a confounding factor, sample size was small and TOF machine may produce some technical errors. Further studies with large sample sizes are required to firmly establish efficacy and safety of drugs used in this study.

#### **CONCLUSIONS**

Onset of action of rocuronium was significantly shorter than v ecuronium. The duration of action of vecuronium of was slight longer than rocuronium. There was no statistically significant difference in intubating conditions. Mean heart rate 10 minutes after intubation was significantly higher in vecuronium group but there was no statistically significant difference in other heamodynamic parameters between the two groups.

#### **REFERENCES**

- 1. Hunter JM. Rocuronium: the newest aminosteriod neuromuscular blocking drug. British journal of anaesthesia, 1996; 76(4): 481-3.
- 2. Fahey MR, Morris RB, Miller RD, Sohn YJ, Cronnelly R, Gencarelli P. Clinical pharmacology of ORG NC45 (NorcuronTM): a new nondepolarizing muscle relaxant. Anesthesiology, Jul, 1981; 55(1): 6-11.

- 3. Veena Chatrath, Iqbal Singh, Raman Chatrath and Neha Arora. Comparison of intubating conditions of Rocuronium Bromide and Vecuronium Bromide with Succinylcholine using timing principle. J Anaesthesiol Clin Phrmacol, Oct-Dec, 2010; 26(4): 493-97.
- 4. Charan J, Biswas T. How to calculate sample size for different study designs in medical research. Indian journal of psychological medicine, Apr-Jun, 2013; 35(2): 121-26.
- 5. Wierda J.M.K.H., A.P.M. De Wit, K, Kuizenga, S. Agaston. Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent. British journal of anaesthesia, 1990; 64: 521-23.
- 6. Bartkowski RR, Witkowski TA, Azad S, Lessin J, MarrA. Rocuronium onset of action: a comparison with atracurium and vecuronium. Anesthesia and Analgesia, 1993; 77:574-78.
- 7. Robertson EN, Hull JM, Verbeck AM, Booij LH. A comparison of rocuronium and vecuronium: the pharmacodynamic, cardio vascular and intra-ocular effects. European Journal of Anaesthesiology, 1994; 9: 116-21.
- 8. Schramm W.M, Strasser, Bartunek A, GILLY H, SPISS C K, Cunningham Anthony. Effects of Rocuronium and Vecuronium on intracranial pressure, mean arterial pressure and heart rate in neurosurgical patients. Survey of Anesthesiology, October, 1997; 41(5): 279.
- 9. Levy JH, Davis GK, Duggan J, Szlam F. Determination of the hemodynamics and histamine release of Rocuronium (Org9426) when administered in increased doses underN<sub>2</sub>O/O2-sufentanil anaesthesia. Anesthesia and Analgesia, 1994; 78:318-321.
- Bharati Neerja, Sharma Sunila, Goel SK. Rocuronium: Time course of action & intubation condition-A comparison with Atracurium & Vecuronium. IJA, 2001; 45: 363-69.
- 11. Lin PL, Liu CC, Fan SZ, Chao A, Shin SC, Tai YT. Comparison of neuromuscular action of rocuronium, a new steroidal non depolarizing agent with vecuronium. Acta anaesthesiologica Sinica, Sep, 1997; 35(3): 127-31.
- 12. Man TT, Cheng JK, Wong KL, Chen CC, Rau RH, Wu KH et al. Tracheal intubation condition- a comparison between one minute after rocuronium alone, one minute after rocuronium combined with atracurium and one minute after atracurium with rocuronium at one minute priming interval. Acta anaesthesiologica Sinica, Dec, 2002; 40(4): 179-83.